NLS immunovia

Immunovia announces that the large retrospective autoimmune disease study, performed in collaboration with Lund University’s IDEA Centre has been finalized. The study, first reported in January 2017, included 315 blood samples and was specifically designed to assess the effectiveness of IMMray blood-based biomarker signatures in differentiating SLE from three other main autoimmune diseases: rheumatoid arthritis, […]

Immunovia has announced that the principal aim of a large retrospective study, performed in collaboration with Lund University’s IDEA Centre, has been achieved. The data confirms that IMMray biomarker signatures can distinguish Systemic Lupus Erythematosus (SLE) from three other main autoimmune diseases, rheumatoid arthritis, Sjögren’s disease and vasculitis with an average accuracy exceeding 90%. These […]

The Swedish diagnostics company Immunovia has won the Stars of Innovation category in the European Small- and Mid-Cap Awards 2016. The nomination is recognition of the company’s stellar performance since listing in Stockholm in December last year. During this period, Immunovia has made major progress in developing the first applications for its IMMray™ blood-based diagnostics […]

Immunovia has successfully completed its SEK 28.7 million rights issue of which the subscription period ended on Monday October 17th. The underwriters, who had guaranteed 52% of the rights issue, will thereby not be assigned any shares through their guarantee. 285,072 new shares, representing 86.5% of the rights issue of maximum 329,451 new shares, were subscribed […]

Immunovia and the University of Liverpool enter into collaboration to validate early detection blood test for pancreatic cancer in a prospective clinical study. In line with Immunovia´s strategy to deliver the first validated test for early diagnosis of pancreatic cancer, the company announced yesterday that the first European site participating in its prospective clinical study […]